BioNTech and InstaDeep have entered into an agreement to establish a joint AI Innovation Lab in London, United Kingdom and Mainz, Germany, with the aim of advancing a portfolio of enterprise-wide digital initiatives in the areas of drug discovery and design, protein engineering and operations.
Entering a multi-year alliance for implementing AI and ML technologies
German biotechnology firm BioNTech and London-headquartered AI product company InstaDeep have announced a multi-year strategic alliance focused on implementing the latest technological advancements for artificial intelligence (AI) and machine learning (ML) to create new immunotherapies for a variety of cancers and infectious diseases.
The long-term partnership builds on the already established alliance that was started in 2019 between InstaDeep and BioNTech.
Ugur Sahin, M.D., CEO and Co-Founder of BioNTech commented:
“We see a significant opportunity at the intersection of AI and immunology by computational design of new precision immunotherapies. This collaboration will expand our digital capabilities and optimize our operations across the value chain by adding InstaDeep’s powerful Artificial Intelligence and Machine Learning expertise. We look forward to working with InstaDeep to advance the next wave of innovation in the field”.
BioNTech and InstaDeep’s joint AI Innovation Lab
BioNTech and InstaDeep will form a joint AI Innovation Lab in London, UK, and Mainz, Germany as part of the agreement, to accelerate a portfolio of drug development, protein engineering, production and supply chain optimisation projects. The AI Innovation Lab will align the innovative technologies of InstaDeep in the fields of artificial intelligence, machine learning, and digitalisation with the deep domain experience of BioNTech in precision immunotherapies, providing access to a broad range of internal and external databases. Creating next-generation vaccines and biopharmaceuticals for prevention and treatment of cancer and infectious diseases, including for COVID-19, will be one of the major research fields of the BioNTech and InstaDeep joint AI Innovation Lab.
Main areas of collaboration
Three main areas will be the subject of strategic collaboration:
Novel Drug Design
BioNTech is accelerating a pipeline of novel mRNA-based vaccines and therapeutics and will use the DeepChainTM protein design platform to create new mRNA sequences for protein targets, including for its RiboMabTM and RiboCytokineTM technologies that use messenger RNA to encode antibodies and cytokines in vivo.
BioNTech and InstaDeep aim to derive insights from public and proprietary meta databases, as well as anonymized patient-relevant data with the use of machine learning and edge analytics to identify novel biological targets and predictive biomarkers.
Manufacturing and Supply Chain Optimisation
To better improve manufacturing and supply chain operations, BioNTech aims to use AI and ML applications. BioNTech strives to provide greater efficiencies in drug production, distribution and supply chain operations by utilizing the novel remarkable advances in robotics and autonomous decision-making algorithms.
InstaDeep has its headquarters in London and was recently nominated as one of the world’s 100 most promising AI start-ups by CB Insights.
Karim Beguir, Co-Founder and CEO of InstaDeep stated:
“Pairing BioNTech’s deep knowledge of the human immune system and scientific data-driven development approach with our AI platform could transform the way we discover and develop new drug classes for patients all over the world. For InstaDeep, the long-term collaboration with BioNTech also means we can further expand on our mission as a company to accelerate the transition to an AI-First world that benefits everyone. Based on the results already achieved by working together, we see an exciting path forward.”
Established in 2014, InstaDeep, with headquarters in London and offices in Paris, Tunis, Lagos, Dubai and Cape Town, is now an EMEA pioneer in AI Business decision-making products. With experience in both research into artificial intelligence and realistic business deployments, the company provides to its partners an AI-first world competitive advantage.
Leveraging its extensive know-how in GPU-accelerated computing, deep learning and reinforcement learning, InstaDeep has built products, such as its novel DeepChainTM protein design platform, that tackles the most complex challenges across a range of industries. Taking advantage of its comprehensive know-how in GPU-accelerated computing, deep learning and reinforcement learning, InstaDeep has created products that can solve the most challenging problems across a variety of industries and niches, such as the novel DeepChainTM protein design platform.
InstaDeep has also developed collaborations with Google DeepMind, Nvidia and Intel, major global leaders in the Artificial Intelligence ecosystem. The company is part of the AI Builders program of Intel and was named by Nvidia as a Preferred Deep Learning Partner.
Please visit www.instadeep.com to learn more.
Biopharmaceutical New Technologies is a next-gen immunotherapy company innovating new therapies for cancer and other serious diseases. BioNTech utilises a large spectrum of therapeutic drug platforms and computer research innovations for facilitating the accelerated development of novel biopharmaceuticals.
The BioNTech broad portfolio of oncology treatments includes personalised and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. BioNTech and its partners are engineering numerous mRNA vaccine candidates for a variety of infectious diseases, including COVID-19, alongside its diverse oncology pipeline, based on their broad experience in the mRNA vaccine development and in-house production capabilities. With several global pharmaceutical partners, including Pfizer, Genmab, Sanofi, Bayer Animal Health, Genentech, Roche Group members, Regeneron, Genevant and Fosun Pharma, BioNTech has formed a wide range of relationships.
For more information, please visit www.BioNTech.de.